TP53BP2 and hepatocellular carcinoma: Downregulation of ASPP2 activates the WNT/β‐catenin pathway contributing to enhanced glycolysis kinase expression, and leading to the promotion of HCC proliferation, glycolysis metabolism, stemness and drug resistance.